Literature DB >> 16809308

Rapid pathogenesis induced by a vesicular stomatitis virus matrix protein mutant: viral pathogenesis is linked to induction of tumor necrosis factor alpha.

Jean Publicover1, Elizabeth Ramsburg, Michael Robek, John K Rose.   

Abstract

Vesicular stomatitis virus (VSV) matrix (M) protein blocks host mRNA export from the nucleus and thereby inhibits interferon induction in infected cells. M mutants with mutations of methionine 51 (M51) lack this shutoff function. We examined pathogenesis of a VSV M mutant with a deletion of M51 (VSVDeltaM51) after intranasal infection of BALB/c mice and found an unexpected phenotype. Mice that received VSVDeltaM51 experienced a more rapid but overall less severe weight loss than mice that received the recombinant wild-type VSV (rwtVSV). Rapid weight loss was not explained by faster initial replication because VSVDeltaM51 replication was controlled faster than rwtVSV replication in the lungs and did not spread systemically like rwtVSV. This faster control of VSVDeltaM51 correlated with a more rapid induction of interferon in the lung. Because tumor necrosis factor alpha (TNF-alpha) is associated with weight loss, we examined TNF-alpha induction in mice infected with rwtVSV or VSVDeltaM51. We found more-rapid induction of TNF-alpha by the mutant at early times after infection, while rwtVSV induced more TNF-alpha later in infection. This result suggested that TNF-alpha induction might explain both the rapid weight loss caused by the mutant and the overall greater weight loss caused by the rwtVSV. Using TNF-alpha knockout mice (C57BL/6 background), we showed that weight loss following rwtVSV infection was greatly reduced in the absence of TNF-alpha. Although the rapid weight loss caused by VSVDeltaM51 was less pronounced in C57BL/6 mice, it was eliminated in the absence of TNF-alpha. These results indicate a role for TNF-alpha in the pathogenesis of VSV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809308      PMCID: PMC1489072          DOI: 10.1128/JVI.00478-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98.

Authors:  J P Rodrigues; D Sitterlin; A Bachi; X Wu; M Wilm; M Carmo-Fonseca; E Izaurralde
Journal:  Mol Cell       Date:  2000-11       Impact factor: 17.970

2.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

Review 3.  Lethal weight loss: the focus shifts to signal transduction.

Authors:  Kevin J Tracey
Journal:  Sci STKE       Date:  2002-04-30

4.  Internalization of adenovirus by alveolar macrophages initiates early proinflammatory signaling during acute respiratory tract infection.

Authors:  Z Zsengellér; K Otake; S A Hossain; P Y Berclaz; B C Trapnell
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

5.  Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.

Authors:  N F Rose; A Roberts; L Buonocore; J K Rose
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge.

Authors:  Robert J Natuk; David Cooper; Min Guo; Priscilla Calderon; Kevin J Wright; Farooq Nasar; Susan Witko; Diane Pawlyk; Margaret Lee; Joanne DeStefano; Donna Tummolo; Aaron S Abramovitz; Seema Gangolli; Narender Kalyan; David K Clarke; R Michael Hendry; John H Eldridge; Stephen A Udem; Jacek Kowalski
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology.

Authors:  Himangi R Jayakar; Michael A Whitt
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

8.  Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.

Authors:  David F Stojdl; Brian D Lichty; Benjamin R tenOever; Jennifer M Paterson; Anthony T Power; Shane Knowles; Ricardo Marius; Jennifer Reynard; Laurent Poliquin; Harold Atkins; Earl G Brown; Russell K Durbin; Joan E Durbin; John Hiscott; John C Bell
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

10.  Recognition of single-stranded RNA viruses by Toll-like receptor 7.

Authors:  Jennifer M Lund; Lena Alexopoulou; Ayuko Sato; Margaret Karow; Niels C Adams; Nicholas W Gale; Akiko Iwasaki; Richard A Flavell
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

View more
  24 in total

1.  In vivo delivery of cytoplasmic RNA virus-derived miRNAs.

Authors:  Ryan A Langlois; Jillian S Shapiro; Alissa M Pham; Benjamin R tenOever
Journal:  Mol Ther       Date:  2011-11-15       Impact factor: 11.454

2.  HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells.

Authors:  Sonja I Gringhuis; Michiel van der Vlist; Linda M van den Berg; Jeroen den Dunnen; Manja Litjens; Teunis B H Geijtenbeek
Journal:  Nat Immunol       Date:  2010-04-04       Impact factor: 25.606

3.  Immune Consequences of in vitro Infection of Human Peripheral Blood Leukocytes with Vesicular Stomatitis Virus.

Authors:  Tomasz Tomczyk; Grażyna Wróbel; Radosław Chaber; Iwona Siemieniec; Egbert Piasecki; Małgorzata Krzystek-Korpacka; Beata U Orzechowska
Journal:  J Innate Immun       Date:  2018-01-06       Impact factor: 7.349

4.  Relationship between within-host fitness and virulence in the vesicular stomatitis virus: correlation with partial decoupling.

Authors:  Victoria Furió; Raquel Garijo; María Durán; Andrés Moya; John C Bell; Rafael Sanjuán
Journal:  J Virol       Date:  2012-09-05       Impact factor: 5.103

5.  Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Authors:  Anthony N van den Pol; Guochao Mao; Anasuya Chattopadhyay; John K Rose; John N Davis
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

6.  The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Authors:  Melissa A Cobleigh; Clinton Bradfield; Yuanjie Liu; Anand Mehta; Michael D Robek
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection.

Authors:  Mark D Trottier; Douglas S Lyles; Carol Shoshkes Reiss
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

8.  Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells.

Authors:  Guido Wollmann; Vitaliy Rogulin; Ian Simon; John K Rose; Anthony N van den Pol
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

9.  Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus.

Authors:  Maryam Ahmed; Tracie R Marino; Shelby Puckett; Nancy D Kock; Douglas S Lyles
Journal:  J Virol       Date:  2008-07-09       Impact factor: 5.103

10.  A mastoparan-derived peptide has broad-spectrum antiviral activity against enveloped viruses.

Authors:  Christopher J Sample; Kathryn E Hudak; Brice E Barefoot; Matthew D Koci; Moses S Wanyonyi; Soman Abraham; Herman F Staats; Elizabeth A Ramsburg
Journal:  Peptides       Date:  2013-07-26       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.